Journal
BIOMARKERS IN MEDICINE
Volume 9, Issue 2, Pages 89-97Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/BMM.14.103
Keywords
biomarker; diagnosis; near-infrared spectroscopy; oxidative stress; Parkinson's disease; plasma
Categories
Funding
- Michael J Fox Foundation
- NIH
- Biogen Idec
- Auspex Pharmaceuticals
- Department of Defense
- Prana Biotechnology, Ltd
- Sanofi
- Brain Canada
- Canadian Institutes of Health Research
- Edmond J Safra Philanthropic Foundation
- National Parkinson Foundation
- Parkinson Society Canada
- Tourette Syndrome Association
- W Garfield Weston Foundation
Ask authors/readers for more resources
Aim: There are no established chemical biomarkers of idiopathic Parkinson's disease (PD). The results of a prior metabolomics-based biomarker study suggested that near-infrared spectroscopy of blood plasma samples may distinguish idiopathic PD from neurologically normal controls. Methods: Near-infrared spectroscopy was used to detect and quantify substrate modifications in blood plasma samples derived from 71 PD subjects enrolled in the PostCEPT observational study and 68 normal control subjects. Results: Near-infrared spectra values were significantly higher in the PD group compared with the control group when adjusted for age and gender (PD: adjusted mean 0.49 [95% CI: 0.45-0.53]; control: adjusted mean 0.40 [95% CI: 0.36-0.44]; p = 0.004, multiple regression). Conclusion: Near-infrared spectra of blood plasma in early-stage idiopathic PD differ from those of non-neurological control subjects. However, the degree of overlap between the groups limits the use of this technique in its present form as a PD biomarker for routine clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available